苏州宜联生物医药有限公司

About 苏州宜联生物医药有限公司

Suzhou Yilian Biomedical Co., Ltd. is an international biomedical company focused on developing internationally competitive antibody-drug conjugates and related technologies. The company was founded by a team with extensive domestic and international experience in the full-process development of innovative ADC drugs, corporate governance, and capital operations. We are dedicated to developing the latest generation of ADC-related technologies and drugs with independent intellectual property rights. We continuously drive technological iteration, establish diverse conjugation drug technology platforms, expand into new disease areas, and conduct international development and cooperation. The company has completed approximately 790 million RMB in Series A and B financing and has been recognized as a leading entrepreneurial team in the Suzhou Industrial Park, a potential unicorn company, a leading Suzhou entrepreneur, and one of the TOP 10 most promising antibody innovation drug companies. We have established a comprehensive R&D center in the Suzhou Industrial Park, covering drug discovery to process development, and have also established subsidiaries in Shanghai and the United States, as well as a production subsidiary in Suzhou.